ALPN I find their idea of directed evolution interesting. Cancer has crazy mutations and mutation rates. To target current neoantigens is obviously not enough because all drugs, IO or chemo, have relapses, progression etc ...
Their directed evolution platform seems like a decent idea on how to anticipate any tumor next move.
from my Dendreon experience I am wary of Mitch Gold. Same kind of apprehension made me miss out on Juno as it was headed by Hans "mr cost density" Bishop. I am very allergic to C suite BS. Oh well, c'est la vie. win some, miss some.
News 
Market Data 
Discover 
